

- 1: Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies. *Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies*. *ESMO Open*. 2022 May 18;7(3):100459. doi: 10.1016/j.esmoop.2022.100459.
- 2: Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S. *Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups*. *Int J Gynecol Cancer*. 2022 Jun 6;32(6):799-803. doi: 10.1136/ijgc-2022-003435. PMID: 35318277.
- 3: Bartoletti M, Bergamini A, Giannone G, Nero C, Musacchio L, Farolfi A, Passarelli A, Kuhn E, Castaldo D, Lombardo V, Di Palma T, Lorusso D, Puglisi F, De Giorgi U, Valabrega G, Schettino C, Scambia G, Capoluongo E, Pignata S. *A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group*. *Int J Gynecol Cancer*. 2022 Mar 21:ijgc-2022-003425. doi: 10.1136/ijgc-2022-003425.
- 4: Froelich MF, Capoluongo E, Kovacs Z, Patton SJ, Lianidou ES, Haselmann V. *The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group "CNAPS/CTC for early detection of cancer"*. *Clin Chem Lab Med*. 2022 Feb 24;60(6):821-829. doi: 10.1515/cclm-2022-0129. PMID: 35218176.
- 5: Ferrucci V, de Antonellis P, Quarantelli F, Asadzadeh F, Bibbò F, Siciliano R, Sorice C, Pisano I, Izzo B, Di Domenico C, Boccia A, Vargas M, Pierri B, Viscardi M, Brandi S, Fusco G, Cerino P, De Pietro L, Furfaro C, Napolitano LA, Paoletta G, Festa L, Marzinotto S, Conte MC, Gentile I, Servillo G, Curcio F, de Cristofaro T, Broccolo F, Capoluongo E, Zollo M. *Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients-A Target for SARS-CoV-2 Propagation*. *Int J Mol Sci*. 2022 Feb 9;23(4):1941. doi: 10.3390/ijms23041941. PMID: 35216056; PMCID: PMC8878976.

- 6: Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Galvano A, Del Re M, Malapelle U, Chiari R, Conte P, Danesi R, Fassan M, Ferrara R, Genuardi M, Ghiorzo P, Gori S, Guadagni F, Marchetti A, Marchetti P, Midiri M, Normanno N, Passiglia F, Pinto C, Silvestris N, Tallini G, Vatrano S, Vincenzi B, Cinieri S, Beretta G. *The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies*. *Crit Rev Oncol Hematol*. 2022 Jan;169:103567. doi: 10.1016/j.critrevonc.2021.103567.
- 7: Chiloiro S, Capoluongo ED, Angelini F, Mariotti F, Grande G, Stigliano E, Vincenzoni F, Bianchi A, Giampietro A, Milardi D, Tartaglione T, Urbani A, Pontecorvi A, De Marinis L, Di Zenzo G. *Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results*. *Endocrine*. 2022 Apr;76(1):224-227. doi: 10.1007/s12020-021-02937-1. Epub 2021 Nov 19. PMID:34797510.
- 8: Chiloiro S, Russo F, Tartaglione T, Capoluongo ED. *Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice*. *J Pers Med*. 2021 Oct 15;11(10):1026. doi: 10.3390/jpm11101026.
- 9: Nardelli C, Granata I, Nunziato M, Setaro M, Carbone F, Zulli C, Pilone V, Capoluongo ED, De Palma GD, Corcione F, Matarese G, Salvatore F, Sacchetti L. *16S rRNA of Mucosal Colon Microbiome and CCL2 Circulating Levels Are Potential Biomarkers in Colorectal Cancer*. *Int J Mol Sci*. 2021 Oct 4;22(19):10747. doi: 10.3390/ijms221910747
- 10: Cobbaert C, Capoluongo ED, Vanstapel FJLA, Bossuyt PMM, Bhattoa HP, Nissen PH, Orth M, Streichert T, Young IS, Macintyre E, Fraser AG, Neumaier M. *Implementation of the new EU IVD regulation - urgent initiatives are needed to avert impending crisis*. *Clin Chem Lab Med*. 2021 Sep 15. doi: 10.1515/cclm-2021-0975.
- 11: Fuso P, Di Salvatore M, Santonocito C, Guarino D, Autilio C, Mulè A, Arciuolo D, Rinninella A, Mignone F, Ramundo M, Di Stefano B, Orlandi A, Capoluongo E, Nicolotti N, Franceschini G, Sanchez AM, Tortora G, Scambia G, Barone C, Cassano A. *Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients*. *J Pers Med*. 2021 Aug 20;11(8):816. doi: 10.3390/jpm11080816.
- 12: Russo A, Incorvaia L, Malapelle U, Del Re M, Capoluongo E, Vincenzi B, Chiari R, Cortesi L, Danesi R, Florena AM, Fontanini G, Gori S, Marchetti A, Normanno N, Pinto C, Sangiolo D, Silvestris N, Tagliaferri P, Tallini G, Cinieri S, Beretta GD. *The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-*

SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Crit Rev Oncol Hematol. 2021 Sep;165:103436. doi: 10.1016/j.critrevonc.2021.103436.

13: Capoluongo E, Nardelli C, Esposito MV, Buonomo AR, Gelzo M, Pinchera B, Zappulo E, Viceconte G, Portella G, Setaro M, Gentile I, Castaldo G. Case Report: *Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma. Front Oncol. 2021 Jul 20*;11:705948. doi: 10.3389/fonc.2021.705948. PMID: 34354952; PMCID: PMC8329552.

14: Ferrucci V, Kong DY, Asadzadeh F, Marrone L, Boccia A, Siciliano R, Criscuolo G, Anastasio C, Quarantelli F, Comegna M, Pisano I, Passariello M, Iacobucci I, Monica RD, Izzo B, Cerino P, Fusco G, Viscardi M, Brandi S, Pierri BM, Borriello G, Tiberio C, Atripaldi L, Bianchi M, Paoletta G, Capoluongo E, Castaldo G, Chiariotti L, Monti M, De Lorenzo C, Yun KS, Pascarella S, Cheong JH, Kim HY, Zollo M. *Long-chain polyphosphates impair SARS-CoV-2 infection and replication. Sci Signal. 2021 Jul 6*;14(690):eabe5040. doi: 10.1126/scisignal.abe5040.

15: Russo A, Incorvaia L, Del Re M, Malapelle U, Capoluongo E, Gristina V, Castiglia M, Danesi R, Fassan M, Giuffrè G, Gori S, Marchetti A, Normanno N, Pinto C, Rossi G, Santini D, Sartore-Bianchi A, Silvestris N, Tagliaferri P, Troncone G, Cinieri S, Beretta GD. *The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. ESMO Open. 2021 Jun*;6(3):100164. doi:10.1016/j.esmoop.2021.100164.

16: De Angelis C, Nardelli C, Concolino P, Pagliuca M, Setaro M, De Paolis E, DePlacido P, Forestieri V, Scaglione GL, Ranieri A, Lombardo B, Pastore L, De Placido S, Capoluongo E. Case Report: *Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. Front Oncol. 2021 Feb 24*;11:602523. doi:10.3389/fonc.2021.602523.

17: Zollo M, Ferrucci V, Izzo B, Quarantelli F, Domenico CD, Comegna M, Paolillo C, Amato F, Siciliano R, Castaldo G, Capoluongo E. *SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods. Diagnostics (Basel). 2021 Feb 12*;11(2):288. doi: 10.3390/diagnostics11020288.

18: Nardelli C, Gentile I, Setaro M, Di Domenico C, Pinchera B, Buonomo AR, Zappulo E, Scotto R, Scaglione GL, Castaldo G, Capoluongo E. *Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium*

periodonticum? **Front Cell Infect Microbiol.** 2021 Feb 15;11:625581. doi: 10.3389/fcimb.2021.625581.

19: Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE. *Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.* **Eur J Cancer.** 2021 Mar;146:30-47. doi: 10.1016/j.ejca.2020.12.023.

20: Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastris K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, Curigliano G. *Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing In Oncology.* **Biomed Hub.** 2020 Sep 14;5(3):182-223.

21: Horgan D, Ciliberto G, Conte P, Curigliano G, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E. *Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.* **Cancers (Basel).** 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583.

22: Minucci A, Scambia G, De Bonis M, De Paolis E, Santonocito C, Fagotti A, Capoluongo E, Concolino P, Urbani A. *BRCA testing delay during the COVID-19 pandemic: How to act?* **Mol Biol Rep.** 2021 Jan;48(1):983-987. doi: 10.1007/s11033-020-06060-8. Epub 2020 Dec 12. PMID: 33313973; PMCID: PMC7733534.

- 23: De Paolis E, De Bonis M, Concolino P, Piermattei A, Fagotti A, Urbani A, Scambia G, Minucci A, Capoluongo E. *Droplet digital PCR for large genomic rearrangements detection: A promising strategy in tissue BRCA1 testing*. *Clin Chim Acta*. 2021 Feb;513:17-24. doi: 10.1016/j.cca.2020.12.001.
- 24: Fania L, Moro F, De Paolis E, Provini A, Salemme A, Mariotti F, Sinagra JLM, Mazzanti C, Ruzzi L, Capoluongo E, Di Zenzo G. *Pemphigus vulgaris in two pairs of siblings from two unrelated Italian families: Human leukocyte antigen genotypes, ST18 mutation and immunological profile*. *J Dermatol*. 2021 Feb;48(2):211-214. doi: 10.1111/1346-8138.15656. Epub 2020 Dec 1. PMID: 33258504.
- 25: Nero C, Ciccarone F, Boldrini L, Lenkowicz J, Paris I, Capoluongo ED, Testa AC, Fagotti A, Valentini V, Scambia G. *Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)*. *Sci Rep*. 2020 Oct 5;10(1):16511. doi: 10.1038/s41598-020-73505-2.
- 26: Canu G, De Paolis E, Righino B, Mazzuccato G, De Paolis G, Capoluongo E, De Rosa MC, Urbani A, Gunes AM, Minucci A. *Identification and in silico characterization of a novel PKLR genotype in a Turkish newborn*. *Mol Biol Rep*. 2020 Oct;47(10):8311-8315. doi: 10.1007/s11033-020-05836-2. Epub 2020 Sep 24.
- 27: Capoluongo E. *PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open*. *Biomed Pharmacother*. 2020 Oct;130:110536. doi: 10.1016/j.biopha.2020.110536.
- 28: Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambia G, Fagotti A. *Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach*. *Gynecol Oncol*. 2020 Sep;158(3):740-746. doi: 10.1016/j.ygyno.2020.06.479.
- 29: Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A. *High resolution melting profiles (HRMPs) obtained by magnetic induction cyler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment*. *Mol Biol Rep*. 2020 Jun;47(6):4897-4903. doi: 10.1007/s11033-020-05504-5.
- 30: Santonocito C, Rizza R, Paris I, Marchis L, Paolillo C, Tiberi G, Scambia G, Capoluongo E. *Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome*. *Cancers (Basel)*. 2020 May 19;12(5):1286. doi: 10.3390/cancers12051286.

- 31:** Capoluongo E, De Matteis E, Cucinotto I, Ronzino G, Santonocito C, Tornesello A, De Giorgio MR, Lucci Cordisco E, Minucci A, Genuardi M. *A new founder BRCA1 haplotype identified in the Puglia region is associated with a specific age-related cancer onset in three unrelated families.* Clin Chem Lab Med. 2020 May 12;59(3):e95-e98. doi: 10.1515/cclm-2020-0389. PMID: 32396136.
- 32:** Salvatore M, Amato A, Florida G, Censi F, Ferrari G, Tosto F, Padoan R, Raia V, Cirilli N, Castaldo G, Capoluongo E, Caruso U, Corbetta C, Taruscio D. *The Italian External Quality Assessment Program for Cystic Fibrosis Sweat Chloride Test: Does Active Participation Improve the Quality?* Int J Environ Res Public Health. 2020 May 4;17(9):3196. doi: 10.3390/ijerph17093196
- 33:** Capoluongo ED, Amato F, Castaldo G. *The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene.* Clin Chem Lab Med. 2020 Jun 25;58(7):1162-1164. doi: 10.1515/cclm-2020-0442.
- 34:** Gallo A, Cancelli C, Ceron E, Covino M, Capoluongo E, Pocino K, Ianiro G, Cammarota G, Gasbarrini A, Montalto M. *Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection.* J Gastroenterol Hepatol. 2020 Nov;35(11):1909-1915. doi: 10.1111/jgh.15072.
- 35:** Moffa S, Mazzuccato G, De Bonis M, De Paolis E, Onori ME, Pontecorvi A, Urbani A, Giaccari A, Capoluongo E, Minucci A. *Identification of two novel LDLR variants by Next Generation Sequencing.* Ann Ist Super Sanita. 2020 Jan- Mar;56(1):122-127. doi: 10.4415/ANN_20_01_17. PMID: 32242544.
- 36:** Gallotta V, Bruno M, Conte C, Giudice MT, Davià F, Moro F, Zannoni GF, Fagotti A, De Bonis M, Capoluongo E, Scambia G, Ferrandina G. *Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.* Eur J Surg Oncol. 2020 Jul;46(7):1327-1333. doi: 10.1016/j.ejso.2020.01.035.
- 37:** Minucci A, Mazzuccato G, D'Indinosante M, Di Nardo L, Concolino P, De Bonis M, Urbani A, Scambia G, Fagotti A, Capoluongo E. *Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by High Resolution Melting Analysis.* Mol Biol Rep. 2020 Feb;47(2):1513-1520. doi: 10.1007/s11033-019-05199-3. Epub 2019 Dec 12. PMID: 31833030.

- 38:** Scaglione GL, Fania L, De Paolis E, De Bonis M, Mazzanti C, Di Zenzo G, Lechiancole S, Messinese S, Capoluongo E. *Evaluation of cutaneous, oral and intestinal microbiota in patients affected by pemphigus and bullous pemphigoid: A pilot study.* **Exp Mol Pathol.** **2020 Feb**;112:104331. doi: 10.1016/j.yexmp.2019.104331.
- 39:** Muscarella LA, Fabrizio FP, De Bonis M, Mancini MT, Balsamo T, Graziano P, Centra F, Sparaneo A, Trombetta D, Bonfitto A, Scagliusi V, Larizza P, Capoluongo ED, Fazio VM. *Automated Workflow for Somatic and Germline Next Generation Sequencing Analysis in Routine Clinical Cancer Diagnostics.* **Cancers (Basel).** **2019 Oct 30**;11(11):1691. doi: 10.3390/cancers11111691.
- 40:** Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S. *BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.* **Diagnostics (Basel).** **2019 Oct 9**;9(4):146. doi: 10.3390/diagnostics9040146.
- 41:** Concolino P, Capoluongo E. *Detection of BRCA1/2 large genomic rearrangements in breast and ovarian cancer patients: an overview of the current methods.* **Expert Rev Mol Diagn.** **2019 Sep**;19(9):795-802. doi: 10.1080/14737159.2019.1657011.
- 42:** Chiloiro S, Capoluongo ED, Tartaglione T, Giampietro A, Bianchi A, Giustina A, Pontecorvi A, De Marinis L. *The Changing Clinical Spectrum of Hypophysitis.* **Trends Endocrinol Metab.** **2019 Sep**;30(9):590-602. doi: 10.1016/j.tem.2019.06.004.
- 43:** Concolino P, Gelli G, Rizza R, Costella A, Scambia G, Capoluongo E. *BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants.* **Int J Mol Sci.** **2019 Jul 12**;20(14):3442. doi: 10.3390/ijms20143442.
- 44:** Chiloiro S, Capoluongo ED, Schinzari G, Concolino P, Rossi E, Martini M, Cocomazzi A, Grande G, Milardi D, Maiorano BA, Giampietro A, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. *First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.* **Front Endocrinol (Lausanne).** **2019 Jun 12**;10:365. doi: 10.3389/fendo.2019.00365. .
- 45:** Gallotta V, Conte C, D'Indinosante M, Capoluongo E, Minucci A, De Rose AM, Ardito F, Giuliantè F, Di Giorgio A, Zannoni GF, Fagotti A, Margreiter C, Scambia G, Ferrandina G. *Prognostic factors value of germline and somatic brca in patients undergoing surgery*

for recurrent ovarian cancer with liver metastases. *Eur J Surg Oncol*. 2019 Nov;45(11):2096-2102. doi: 10.1016/j.ejso.2019.06.023.

46: Giuliani F, Panettieri E, Ardito F, De Rose A, Pocino K, Autilio C, Paolillo C, Capoluongo ED. *Circulating tumor cell-related transcripts in blood as prognostic biomarkers of early recurrence after liver resection for colorectal metastases*. *Int J Biol Markers*. 2019 Sep;34(3):269-275. doi:10.1177/1724600819849438.

47: Ruggiero A, Pocino K, Catalano M, Maurizi P, D'Ambra M, Rizzo D, Triarico S, Attinà G, Mastrangelo S, Capoluongo ED. *Serum biomarkers for sepsis in children with febrile neutropenia and cancer*. *J Biol Regul Homeost Agents*. 2019 May-Jun;33(3):999-1003. PMID: 31198017.

48: De Paolis E, Scaglione GL, De Bonis M, Minucci A, Capoluongo E. *CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype*. *Clin Chem Lab Med*. 2019 Oct 25;57(11):1650-1667. doi: 10.1515/cclm-2018-1208.

49: Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group. *Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives*. *Crit Rev Oncol Hematol*. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012.

50: Minucci A, Onori ME, Mazzuccato G, Urbani A, Capoluongo E. *Molecular basis of favism triggered by ingestion of frozen pumpkin cross-contaminated with fava beans*. *Clin Biochem*. 2019 Jul;69:45-47. doi: 10.1016/j.clinbiochem.2019.05.013.

51: Cappellani D, Brancatella A, Kaufmann M, Minucci A, Vignali E, Canale D, De Paolis E, Capoluongo E, Cetani F, Jones G, Marcocci C. *Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in the CYP24A1 Gene: A Case Report and Review of the Literature*. *Case Rep Endocrinol*. 2019 Apr 8;2019:4982621. doi: 10.1155/2019/4982621.

52: De Bonis M, De Paolis E, Scaglione GL, Fania L, Lavieri MM, Mazzanti C, Di Zenzo G, Minucci A, Capoluongo E. *High-resolution melting analysis to screen the ST18 gene functional risk variant for pemphigus vulgaris: The occasion to open a debate on its usefulness in clinical setting*. *Exp Mol Pathol*. 2019 Jun;108:57-63. doi: 10.1016/j.yexmp.2019.03.009.